Calendrier des promotions Oculis Holding AG
Calendrier avancé
Graphique simple
À propos de l'entreprise Oculis Holding AG
Oculis Holding AG, a clinical-stage biopharmaceutical company, develops novel topical treatments for ophthalmic diseases for both back- and front-of-the-eye. The company's lead candidate is OCS-01, a topical dexamethasone formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for keratoconjunctivitis sicca, or dry eye disease; and OCS-05, a novel neuroprotective agent for acute optic neuritis and other neuro-ophtha disorders, such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The company is based in Zug, Switzerland.Paramètres de base
IPO date
2023-03-02
ISIN
CH1242303498
Industry
Biotechnology
Sector
Health Care
Валюта
usd
Валюта отчета
chf
Сайт
Grade
Sous-estimation
Nom | Signification | Grade |
P/S | 317.87 | 1 |
P/BV | 9.18 | 1 |
P/E | 0 | 0 |
Efficacité
Nom | Signification | Grade |
ROA | -73.09 | 0 |
ROE | -102.66 | 0 |
ROIC | 0 | 0 |
Dividendes
Nom | Signification | Grade |
Rendement en dividendes | 0 | 0 |
DSI | 0 | 0 |
Croissance moyenne du dividende | 0 | 0 |
Devoir
Nom | Signification | Grade |
Debt/EBITDA | -0.0258 | 10 |
Debt/Ratio | 0.0098 | 10 |
Debt/Equity | 0.6401 | 9 |
Impulsion de croissance
Nom | Signification | Grade |
Rentabilité Revenue, % | -11.08 | 0 |
Rentabilité Ebitda, % | 277.99 | 10 |
Rentabilité EPS, % | 282.88 | 10 |
paper.price.prices
Prix | Common.min. | Common.max. | Changement | paper.changes_in_industry | paper.changes_in_index | |
common.calendar.number_days.1 | 19.02 $ | 0 $ | 0 $ | 0 % | 0 % | 0 % |
common.calendar.number_days.7d | 19.79 $ | 0 $ | 0 $ | -3.89 % | 0 % | 0 % |
common.calendar.number_days.30d | 19.01 $ | 19.02 $ | 19.92 $ | 0.05 % | 0 % | 0 % |
common.calendar.number_days.90d | 16.75 $ | 14.8 $ | 19.92 $ | 13.55 % | 0 % | 0 % |
common.calendar.number_days.180d | 22.1 $ | 14.37 $ | 22.91 $ | -13.94 % | 0 % | 0 % |
common.calendar.number_days.1y | 12.05 $ | 10.94 $ | 22.91 $ | 57.84 % | 0 % | 0 % |
common.calendar.number_days.3y | 9.86 $ | 6.99 $ | 22.91 $ | 92.9 % | 0 % | 0 % |
common.calendar.number_days.5y | 6.99 $ | 6.99 $ | 22.91 $ | 272.1 % | 0 % | 0 % |
common.calendar.number_days.10y | 6.99 $ | 6.99 $ | 22.91 $ | 272.1 % | 0 % | 0 % |
common.calendar.number_days.ytd | 22.91 $ | 14.37 $ | 22.91 $ | -16.98 % | 0 % | 0 % |
Principaux propriétaires
Entreprises similaires
P/E & P/BV
Gestion d'entreprise
Superviseur | Titre d'emploi | Paiement | Année de naissance |
Dr. Riad Sherif M.B.A., M.D. | CEO & Director | N/A | 1968 (57 années) |
Ms. Sylvia Cheung | Chief Financial Officer | N/A | 1975 (50 années) |
Mr. Páll Ragnar Jóhannesson | Chief Business Officer | N/A | 1982 (43 année) |
Ms. Rebecca Weil | Chief Commercial Officer | N/A | |
Dr. Ramin Tadayoni M.D., Ph.D. | Chief Scientific Officer | N/A | |
Ms. Virginia R. Dean | Chief Human Resources Officer | N/A | 1967 (58 années) |
Dr. Bastian Dehmel M.D. | Chief Development Officer | N/A | 1971 (54 année) |
Dr. Snehal Shah Pharm.D. | President of Research & Development | N/A | |
Dr. Sharon Klier M.D., M.P.H. | Chief Development Officer |
Informations sur l'entreprise
Adresse: Switzerland, Zug, Bahnhofstrasse 7 - Ouvrir dans google maps, Ouvrir les cartes yandex
Site web: https://oculis.com
Site web: https://oculis.com